Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement
Aurinia Pharmaceuticals has reached a patent settlement with Teva Pharmaceutical Industries, preventing Teva from launching a generic version of Lupkynis in the U.S. until December 7, 2036. This agreement removes a significant generic threat, strengthening Aurinia's intellectual property protection and driving an after-hours stock increase of up to 6%. The company still faces litigation from other generic challengers but is advancing its pipeline with new studies and drug candidates.
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals has settled patent infringement litigation with Teva Pharmaceuticals regarding Teva's generic voclosporin oral capsules. The settlement confirms Aurinia's patents are valid and enforceable, expiring in December 2037, and prevents Teva from launching its generic product before December 7, 2036, pending FDA approval. This agreement provides Aurinia with extended market exclusivity for its voclosporin product, Lupkynis, which is used for lupus nephritis treatment, and resulted in a 6% rise in Aurinia's stock.
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
TD Cowen has reiterated its Buy rating for Aurinia Pharmaceuticals (AUPH.US), maintaining a target price of $17. This indicates continued confidence from the firm in the company's financial outlook and stock performance.
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules
Aurinia Pharmaceuticals Inc. and its subsidiary, Aurinia Pharma U.S., Inc., have reached a settlement agreement with Teva Pharmaceuticals Inc. concerning patent infringement litigation. The dispute was related to Teva's Abbreviated New Drug Application (ANDA) for generic 7.9 mg voclosporin oral capsules. The settlement was announced via a Form 8-K filing on August 19, 2026, though specific financial details or timelines were not disclosed.
AUPH Stock Rallies 6% After-Hours — Here’s Why
Aurinia Pharmaceuticals (AUPH) stock rallied after-hours following a patent settlement with Teva Pharmaceuticals regarding its drug LUPKYNIS. The agreement prevents Teva from launching a generic version of LUPKYNIS before December 2036, extending Aurinia's market exclusivity. This news boosted retail investor sentiment, with many anticipating positive outcomes from ongoing litigation and potential buyout interest in Aurinia.
Aurinia stock falls on Teva patent settlement for voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares declined 2% after announcing a patent settlement with Teva Pharmaceuticals Inc. The settlement permits Teva to launch a generic version of voclosporin no earlier than December 7, 2036, though this is contingent on FDA approval and other factors. Aurinia's patent infringement actions against several other pharmaceutical companies for generic voclosporin remain ongoing.
(AUPH) Risk Channels and Responsive Allocation
The article analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment despite potential long-term strength. It details an exceptional 43.3:1 risk-reward setup targeting an 11.7% gain versus 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $17.67. This comes despite its CEO and other insiders acquiring a significant number of shares recently. The company beat EPS estimates but missed revenue forecasts in its latest quarterly report.
Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy
Wall Street Zen downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from "strong buy" to "buy" due to revenue falling short of expectations, despite beating EPS estimates. The broader analyst consensus remains "hold" with an average price target of $17.67. Insider buying, including a significant purchase by the CEO, indicates confidence in the company, with insiders owning 10.4% of the stock.
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance
Aurinia Pharmaceuticals reported strong Q2 2026 results with increased revenue and net income, alongside reaffirming its 2026 guidance for total revenue and net product sales. This performance supports the near-term investment narrative for its primary drug, LUPKYNIS, but also highlights the ongoing concentration risk around this single product. Analysts have varying long-term projections, indicating different perspectives on the company's future upside beyond the current guidance.
Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported its financial results for the three and six months ended June 30, 2026, highlighting significant net product revenue for LUPKYNIS and a strong balance sheet. The company also provided an update on its recent business progress, including advancements in its pipeline programs and ongoing commercial success. These results reflect continued growth and strategic execution in the biopharmaceutical sector.
Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28— 10-Q Summary
Aurinia Pharmaceuticals Inc. reported its 2026 quarterly results, with revenue reaching $83.22M and diluted EPS of $0.28, marking significant increases compared to the previous year. The growth was attributed to higher product sales, improved operating performance, and increased market penetration of LUPKYNIS. The company also highlighted clinical advancements, pipeline expansion, and enhanced manufacturing capacity.
Aurinia Pharmaceuticals (AUPH) Earnings Date and Reports 2026
Aurinia Pharmaceuticals (AUPH) announced its Q2 2026 earnings, reporting an EPS of $0.28, surpassing the consensus estimate of $0.24. However, quarterly revenue of $58.57 million fell short of analysts' expectations. The company also provided FY 2026 revenue guidance of $315.0 million-$325.0 million, slightly below the consensus estimate.
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance
Aurinia Pharmaceuticals reported strong Q2 2026 results with increased revenue and net income, alongside reaffirming its 2026 revenue guidance. This performance reinforces the company's near-term outlook for its LUPKYNIS drug, despite ongoing concerns about its reliance on a single product and future pipeline development. The article discusses how these results impact the investment narrative, highlighting both the company's current profitability and potential long-term risks.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals announced strong financial results for the three and six months ended June 30, 2026, with significant increases in total revenue, net product sales, and net income compared to the previous year. The company also reiterated its 2026 revenue guidance and provided updates on its clinical development programs, including the initiation of the PRESERVE study for LUPKYNIS and further clinical development of aritinercept for autoimmune diseases.
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M
Aurinia Pharmaceuticals Inc. (AUPH) reported Q2 revenue of $83.2 million, surpassing the FactSet estimate of $80.4 million. The article also briefly mentions Unity Software's Q4 earnings, which showed a 35% year-over-year revenue increase to $609 million, exceeding the consensus estimate, despite a quarterly loss of 66 cents per share.
Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance
Aurinia Pharmaceuticals announced its Q2 2026 financial results, reporting $83.2 million in revenue and $37.4 million in net income. The company also reiterated its full-year 2026 revenue guidance of $315 million to $325 million. Key highlights include strong sales for LUPKYNIS and advancements in clinical development programs.
AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook
Aurinia Pharmaceuticals (AUPH) reported strong double-digit year-over-year growth in revenue and net income, primarily due to LUPKYNIS sales and improved margins. The company's 2026 guidance anticipates continued growth in revenue and product sales. Additionally, new clinical programs and share repurchases indicate ongoing positive business momentum for AUPH.
Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story
Aurinia Pharmaceuticals (AUPH) is expanding its clinical pipeline with a new Phase 1/2 trial for aritinercept, targeting generalized myasthenia gravis. The double-blind, placebo-controlled study will investigate the safety and efficacy of the dual BAFF/APRIL inhibitor in improving muscle weakness in this chronic autoimmune condition. This move diversifies Aurinia's portfolio beyond kidney disease into neurology, potentially supporting a higher valuation if early data are promising.
(AUPH) Movement as an Input in Quant Signal Sets
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is showing weak near and mid-term sentiment, challenging a positive long-term outlook, with support currently being tested. The article provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. It highlights a significant 42.0:1 risk-reward setup targeting an 11.4% gain versus a 0.3% risk.
Lazard Asset Management LLC Sells 106,820 Shares of Aurinia Pharmaceuticals Inc $AUPH
Lazard Asset Management LLC significantly reduced its stake in Aurinia Pharmaceuticals (NASDAQ:AUPH) by 43.7% in the first quarter, selling 106,820 shares but still retaining 137,355 shares valued at $2.04 million. Despite this, other institutional investors generally increased their positions, with hedge funds and institutional investors collectively owning 36.83% of the company's stock. Analysts currently hold a consensus "Hold" rating for AUPH with an average price target of $17.33, and CEO Kevin Tang recently purchased over 200,000 shares.
Aurinia Pharmaceuticals Inc Revenue Breakdown – NASDAQ:AUPH
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) generated $283.06 million USD in revenue last year, primarily from its Therapeutic Drugs segment. This marks an increase from the previous year's $235.13 million USD. The United States was the largest contributor to revenue, accounting for $263.84 million USD.
Aurinia Pharma earnings up next as growth momentum faces test By Investing.com
Aurinia Pharmaceuticals Inc. is set to report second-quarter earnings, with analysts anticipating increased revenue but a sequential decline in EPS, raising concerns about profitability. The focus will be on the sales trajectory of its lupus treatment LUPKYNIS, margin dynamics, and updates on its pipeline. Despite the mixed outlook, Wall Street maintains a "buy" rating for the stock.
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aurinia Pharmaceuticals Inc (AUPH), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock currently trades between a resistance of $16.58 and support of $14.31, making it suitable for range-bound swing trading. While individual indicators show mixed signals (e.g., MACD as Sell, StochRSI as Buy), the overall technical analysis and moving averages currently suggest a Neutral signal for Aurinia Pharmaceuticals Inc.
Aurinia Pharma earnings up next as growth momentum faces test
Aurinia Pharmaceuticals Inc. (AUPH) is set to report its second-quarter earnings, with analysts expecting $0.23 per share on $80.6 million in revenue, an increase from the prior year. Despite projected revenue growth, sequential earnings estimates have declined, raising concerns about profitability margins amidst scaling commercial operations for its lupus treatment, LUPKYNIS. Investors will be focused on the company's revenue trajectory, margin dynamics, and pipeline progress, particularly updates on the PRESERVE study and aritinercept.
Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Aurinia Pharmaceuticals Inc (AUPH), detailing its current risk score, beta value, and various volatility and liquidity metrics. AUPH has a risk assessment score of 7.19, ranking 16 out of 384 in its industry, and a beta of 1.43, indicating higher volatility compared to the S&P 500. The report also highlights its historical daily returns, maximum drawdowns, and Sharpe Ratios over different periods.
Aurinia Pharma earnings up next as growth momentum faces test By Investing.com
Aurinia Pharmaceuticals Inc. is set to release its second-quarter results, with analysts expecting earnings of $0.23 per share on revenue of $80.6 million. Investors will focus on the continued revenue growth of its lupus treatment LUPKYNIS and the company's profit margins, especially since sequential EPS estimates have declined despite rising revenue forecasts. Wall Street maintains a "buy" rating for the stock, with a mean price target of $17.00.
Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis
Aurinia Pharmaceuticals Inc (AUPH) has a current valuation score of 5.10, placing it in the lower ranks of the Biotechnology & Medical Research industry. Its P/E ratio is 6.71, significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
AUPH|Aurinia Pharmaceuticals Inc|Price:15.215|Chg%:-0.135
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in therapies for autoimmune diseases. Its primary product is LUPKYNIS (voclosporin) for lupus nephritis, which it sells in the U.S. and to Otsuka Pharmaceutical for European and Japanese markets. The company is also developing aritinercept (AUR200) for other autoimmune conditions.
Aurinia Pharmaceuticals Inc. Revenue Breakdown – LS:A1W7D4
Aurinia Pharmaceuticals Inc. generated €241.00 million in revenue last year, primarily from its Therapeutic Drugs segment. This represents an increase from the previous year's revenue of €227.13 million. The United States was the largest contributor to this revenue, accounting for €224.64 million last year.
AUPH|Aurinia Pharmaceuticals Inc|Price:15.350|Chg%:+0.110
This article provides a detailed financial overview of Aurinia Pharmaceuticals Inc (AUPH), including its stock performance, market capitalization, and key financial indicators. It presents extensive quarterly and annual data for income statements, balance sheets, and cash flow statements, along with analyst ratings and upcoming earnings dates. The content also addresses frequently asked questions regarding the company's financial metrics based on its FY2025 earnings report.
AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160
Aurinia Pharmaceuticals Inc. (AUPH) shows healthy fundamentals and high growth potential, though its valuation is considered fair. Analysts have given the stock a "Buy" rating with a target price of $17.00, suggesting an 8.70% upside. The company specializes in therapies for autoimmune diseases, with its primary product LUPKYNIS for lupus nephritis, and revenue has grown significantly over the past three years.
TradingKey
This article provides an in-depth cash flow statement analysis for Aurinia Pharmaceuticals Inc (AUPH), offering both quarterly and annual data. It details operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The page also includes an FAQ section explaining key cash flow concepts and their relevance to AUPH's financial health.
AUPH Q2'26 Earnings: revenue estimate is 80.45M USD
Aurinia Pharmaceuticals Inc. (AUPH) is scheduled to release its Q2'26 earnings on July 30th. The company anticipates revenue of $80.45 million and earnings per share (EPS) of $0.24 for the quarter. This article provides a historical overview of AUPH's reported and estimated revenues and EPS for previous quarters.
Liquidity Mapping Around (AUPH) Price Events
Aurinia Pharmaceuticals Inc (AUPH) is showing weak near and mid-term sentiment, despite a strong long-term outlook. The stock is currently testing support, and if it holds, resistance is expected next, with an exceptional risk-reward setup targeting an 11.4% gain. The article outlines different AI-generated trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies.
Aurinia Pharmaceuticals Inc (AUPH) Earnings, Actual EPS, EPS Estimates & Results
This article provides an overview of Aurinia Pharmaceuticals Inc.'s (AUPH) earnings data, including upcoming and historical EPS and revenue reports. It highlights past earning beats and lists recent news and trending discussions related to the company. The company's next earnings report for Q2 '26 is estimated for July 30, with an estimated EPS of $0.24 and revenue of $80.45 million.
Aurinia Pharmaceuticals Inc (AUPH) Fundamental & Financial Data
This article provides fundamental and financial data for Aurinia Pharmaceuticals Inc (AUPH), including its current stock price, market capitalization, P/E ratio, and 52-week high/low. It also lists recent news regarding the company, such as its upgrade to "Strong Buy" by Zacks and the initiation of a new study for its drug LUPKYNIS in lupus nephritis patients. The page also shows trending tickers and community discussions related to other stocks.
Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary
Aurinia Pharmaceuticals (AUPH) reported strong Q1 2026 earnings, with total revenue increasing 24% year-over-year to $77.7 million, driven by LUPKYNIS sales. Net income surged 48% to $34.4 million, and the company saw significant improvements in gross margin and cash flow from operations. The outlook for 2026 includes total revenue guidance of $315–$325 million, representing 11–15% growth over 2025.
Aurinia Pharmaceuticals (AUPH) Proxy filing Summary
Aurinia Pharmaceuticals will hold its annual general meeting virtually on June 3, 2026, where shareholders will vote on director elections, auditor appointment, and executive compensation. Only shareholders of record as of April 14, 2026, are eligible to vote. The company's board of directors is composed of five members, with 80% independent, and has robust corporate governance practices including independent committees and annual self-evaluations.
Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary
Aurinia Pharmaceuticals (AUPH) has released a proxy filing summary detailing their Annual General Meeting scheduled for June 14, 2024. Key proposals include amendments to the Equity Incentive Plan, specifically reducing the proposed increase in reserved shares from 11,375,000 to 8,500,000, bringing the total to 32,315,115 shares or 22.7% of outstanding shares. Shareholders can vote online, by mail, telephone, or internet, and the Board of Directors retains authority over the plan's administration.
Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary
Aurinia Pharmaceuticals reported strong Q1 2026 results, with total revenue increasing 24% year-over-year to $77.7 million, driven by higher LUPKYNIS sales. Net income surged 48% to $34.4 million, and operating cash flows significantly improved. The company also saw significant management changes and provided positive full-year 2026 guidance.
Aurinia Pharmaceuticals (AUPH) Q4 2024 earnings summary
Aurinia Pharmaceuticals (AUPH) reported significant growth and returned to profitability in Q4 and full year 2024, driven by record net product sales for Lupkynis. The company achieved $1.4M net income in Q4 and $5.8M for the full year, a notable turnaround from losses in 2023, while strategically restructuring for improved efficiency. Aurinia also provided a positive outlook for 2025 with expected total revenue between $250M–$260M and initiated a Phase 1 study for AUR-200.
Aurinia Pharmaceuticals (AUPH) 2024 Cantor Fitzgerald Global Healthcare Conference summary
Aurinia Pharmaceuticals (AUPH) presented at the 2024 Cantor Fitzgerald Global Healthcare Conference, highlighting strong financial performance with projected 2024 revenue of $210–$220 million and $330 million cash with no debt. The company is advancing global expansion for its lupus nephritis drug and progressing AUR-200, a BCMA-based BAFF/APRIL inhibitor, through early-stage clinical trials. Key growth drivers include stable patient enrollments, increased hospital orders, and improved therapy persistency, while strategic focus remains on commercial success and pipeline development.
Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary
Aurinia Pharmaceuticals (AUPH) released a proxy filing summary detailing strong 2024 LUPKYNIS sales, cash flow, and share repurchases. Shareholders will vote on directors, auditor appointment, a non-binding say-on-pay, and an amendment to the Equity Incentive Plan. The company also highlighted its updated corporate governance, including a reduced board size and independent committees.
Aurinia Pharmaceuticals (AUPH) Q4 2025 earnings summary
Aurinia Pharmaceuticals (AUPH) reported strong Q4 and full-year 2025 results, with LUPKYNIS sales growing 25% year-over-year to $271.3 million. The company's net income soared to $287.2 million, largely due to an income tax benefit. For 2026, Aurinia forecasts total revenue of $315–$325 million, reflecting continued growth despite new market entrants, and plans to advance its aritinercept clinical programs.
Aurinia Pharmaceuticals (AUPH) Jefferies 2024 Global Healthcare Conference Summary
Aurinia Pharmaceuticals presented a summary of its performance and outlook at the Jefferies 2024 Global Healthcare Conference. The company reported strong LUPKYNIS revenue growth, projecting to be cash flow positive in Q2, and highlighted efforts in market development, patient engagement, and product differentiation. Aurinia Pharmaceuticals detailed the drug's clinical benefits, market expansion plans, and financial health, emphasizing its significant cash reserves and non-dilutive capital from the Otsuka partnership.
bullish divergence on the hourly has held above support at 15.50, i like the stock 😀
The article discusses a bullish divergence observed on the hourly chart for Aurinia Pharmaceuticals (AUPH.US). The stock has maintained support above 15.50, described by the author as a positive indicator. The short post expresses confidence in the stock's performance.
Price to earnings forward of Aurinia Pharmaceuticals Inc. – SWB:IKAP
This article focuses on the "Price to earnings forward" metric for Aurinia Pharmaceuticals Inc. (IKAP) on the Stuttgart Stock Exchange. The content provided is minimal and appears to be a stub for financial data, indicating "No trades" for the market, suggesting a lack of available data or an inactive market period.
Is Aurinia Pharmaceuticals (AUPH) Using Combination LN Trials to Redefine Its LUPKYNIS Strategy?
Aurinia Pharmaceuticals (AUPH) has initiated a Phase 4 study (PRESERVE) to evaluate its lupus nephritis drug, LUPKYNIS, in combination with other approved biologics. This trial aims to assess if combination therapies can improve treatment regimens and usage patterns, potentially influencing Aurinia's long-term investment narrative. While the study supports the LUPKYNIS story, near-term focus remains on revenue guidance, exclusivity, and generic challenges for the company.
Liquidity Mapping Around (AUPH) Price Events
Quantitative Research Desk provides a "Liquidity Mapping" analysis for Aurinia Pharmaceuticals Inc (AUPH). The analysis suggests a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels.
